Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is capable of selectively inducing apoptosis of cancer cells, is a potential targeted drug for cancer therapy. Many clinical trials have verified the safety, tolerability, and therapeutic efficacy of TRAIL or TRAIL agonists in patients. However, the resistance to TRAIL in multiple cancer cells resulted in limited treatment response and poor prognosis. In this review, the molecular mechanisms of TRAIL resistance in cancer cells are summarized. How TRAIL receptors, structure of the cellular membrane, the Protein Kinase B (Akt) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways involve in regulating TRAIL resistance is described. A full understanding of the exact molecular mechanisms of TRAIL resistance in cancer cells could help to design more suitable strategies and new drugs to overcome TRAIL resistance and obtain better therapeutic outcomes.
Keywords: TRAIL, molecular mechanism, resistance, death receptor, AKt, lipid raft, NF-κB, cancer.
Current Pharmaceutical Design
Title:The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs
Volume: 20 Issue: 42
Author(s): Feng Wang, Junsheng Lin and Ruian Xu
Affiliation:
Keywords: TRAIL, molecular mechanism, resistance, death receptor, AKt, lipid raft, NF-κB, cancer.
Abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is capable of selectively inducing apoptosis of cancer cells, is a potential targeted drug for cancer therapy. Many clinical trials have verified the safety, tolerability, and therapeutic efficacy of TRAIL or TRAIL agonists in patients. However, the resistance to TRAIL in multiple cancer cells resulted in limited treatment response and poor prognosis. In this review, the molecular mechanisms of TRAIL resistance in cancer cells are summarized. How TRAIL receptors, structure of the cellular membrane, the Protein Kinase B (Akt) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways involve in regulating TRAIL resistance is described. A full understanding of the exact molecular mechanisms of TRAIL resistance in cancer cells could help to design more suitable strategies and new drugs to overcome TRAIL resistance and obtain better therapeutic outcomes.
Export Options
About this article
Cite this article as:
Wang Feng, Lin Junsheng and Xu Ruian, The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs, Current Pharmaceutical Design 2014; 20 (42) . https://dx.doi.org/10.2174/1381612820666140929100735
DOI https://dx.doi.org/10.2174/1381612820666140929100735 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy
Current Medicinal Chemistry Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Biology of Cox-2: An Application in Cancer Therapeutics
Current Drug Targets LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers
Current Cancer Drug Targets Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
Current Stem Cell Research & Therapy Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy Cancer Chemoprevention by Targeting the Epigenome
Current Drug Targets Anticancer Activity and DNA Binding of 4-Alkylenediamines Modified Naphthalimide Derivatives
Letters in Drug Design & Discovery Fertility Drugs and Ovarian Cancer
Current Cancer Drug Targets Polymer Membrane and Cell Models for Drug Discovery
Combinatorial Chemistry & High Throughput Screening Chemical Constituents and Cytotoxicity of Euphorbia vajravelui
Letters in Organic Chemistry A Proteomics Study of the Subacute Toxicity of Rat Brain after Long- Term Exposure of <i>Gelsemium elegans</i>
Current Molecular Pharmacology Endoglin (CD105): A Target for Anti-angiogenetic Cancer Therapy
Current Drug Targets Genetic and Epigenetic Studies for Determining Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Local Recurrence vs Radiotherapy-Induced Edema in Advanced Laryngeal Carcinoma: Is FDG PET/CT Up to the Challenge?
Current Molecular Imaging (Discontinued) Combined Angiogenic and Osteogenic Factor Delivery for Bone Regenerative Engineering
Current Pharmaceutical Design How to Inhibit Telomerase Activity for Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis
Current Drug Targets Anti-cancer Effects of Curcumin on Head and Neck Cancers
Anti-Cancer Agents in Medicinal Chemistry Applications of Aptamers in Targeted Imaging: State of the Art
Current Topics in Medicinal Chemistry